{"filing":{"accession_number":"0001213900-26-110516","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"ea0308988-6k_neurosense.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026110516/ea0308988-6k_neurosense.htm"},"events":[{"id":36010,"run_id":33198,"accession_number":"0001213900-26-110516","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NeuroSense announced the filing of a U.S. patent application for PrimeC covering treatment of traumatic brain injury (TBI) and related CNS injuries. This represents a material strategic and operational development—expansion of the company's intellectual property portfolio and product pipeline beyond its primary ALS focus into a large, underserved market with no approved disease-modifying therapies. The filing strengthens IP position and creates foundation for future partnerships and non-dilutive funding, directly supporting long-term commercial value creation. While not a discrete M\u0026A, financing, or clinical-trial event, it is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's growth prospects and asset value.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-10-19","form":"6-K","submitted_at":null,"items":[{"id":40279,"accession_number":"0001213900-26-110516","item_number":"EX-99.1","item_title":"ea030898801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NeuroSense announced the filing of a U.S. patent application for PrimeC covering treatment of traumatic brain injury (TBI) and related CNS injuries. This represents a material strategic and operational development—expansion of the company's intellectual property portfolio and product pipeline beyond its primary ALS focus into a large, underserved market with no approved disease-modifying therapies. The filing strengthens IP position and creates foundation for future partnerships and non-dilutive funding, directly supporting long-term commercial value creation. While not a discrete M\u0026A, financing, or clinical-trial event, it is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's growth prospects and asset value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:48:38.146175+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40279,"accession_number":"0001213900-26-110516","item_number":"EX-99.1","item_title":"ea030898801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NeuroSense announced the filing of a U.S. patent application for PrimeC covering treatment of traumatic brain injury (TBI) and related CNS injuries. This represents a material strategic and operational development—expansion of the company's intellectual property portfolio and product pipeline beyond its primary ALS focus into a large, underserved market with no approved disease-modifying therapies. The filing strengthens IP position and creates foundation for future partnerships and non-dilutive funding, directly supporting long-term commercial value creation. While not a discrete M\u0026A, financing, or clinical-trial event, it is a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's growth prospects and asset value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:48:38.146175+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-10-19"}]}